Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-01-15
2008-01-15
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388800, C530S388850, C530S391700, C424S133100, C424S141100, C424S155100, C424S181100, C424S183100, C435S069600, C435S328000, C435S330000
Reexamination Certificate
active
10058069
ABSTRACT:
Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.
REFERENCES:
patent: 5435990 (1995-07-01), Cheng et al.
patent: 5512443 (1996-04-01), Schlom et al.
patent: 5756065 (1998-05-01), Wilson et al.
patent: 5877291 (1999-03-01), Mezes et al.
patent: 5891996 (1999-04-01), Mateo de Acosta del Rio et al.
patent: 5892019 (1999-04-01), Schlom et al.
patent: 5892020 (1999-04-01), Mezes et al.
patent: 5976531 (1999-11-01), Mezes et al.
patent: 5993813 (1999-11-01), Mezes et al.
patent: 6051225 (2000-04-01), Mezes et al.
patent: 6060273 (2000-05-01), Dirks et al.
patent: 6103889 (2000-08-01), Whitlow et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6348581 (2002-02-01), Anderson et al.
patent: 6897044 (2005-05-01), Braslawsky et al.
patent: 0 365 997 (1994-09-01), None
patent: 0 327 378 (1996-11-01), None
patent: 0 394 277 (1998-01-01), None
patent: WO 89/01783 (1989-02-01), None
patent: WO 9413806 (1994-06-01), None
patent: WO 95 09917 (1995-04-01), None
patent: WO 97/11370 (1997-03-01), None
patent: WO 98 05787 (1998-02-01), None
patent: WO 98/11241 (1998-03-01), None
patent: WO 99 36105 (1999-07-01), None
patent: WO 99/43816 (1999-09-01), None
patent: WO 00/26394 (2000-05-01), None
patent: WO 200026394 (2000-05-01), None
Rudikoff et al. Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979-1983.
Goel et al. Journal of Biochemistry, 127:829-836, May 2000.
Pavlinkova et al. The Journal of Nuclear Medicine, 40(9):1536-1546, Sep. 1999.
Pavlinkova et al. Clinical Cancer Research, 5:2613-2619, Sep. 1999.
Slavin-Chiorini et al. International Journal of Cancer, 53:97-103, 1993.
Fundamental Immunology. 242, William E. Paul, M.D. ed., 3rd ed. 1993.
Gillies et al. Human Antibodies and Hybridomas, 1(1):47-54, 1990.
Beresford et al. International Journal of Cancer, 81(6):911-917, Jun. 11, 1999.
Tankersley D. L. Immunological Reviews, 139:159-172, 1994.
Kleinveld H. A. et al. Scandinavian Journal of Rheumatology Supplement, Suppl. 75 :157-163, 1988.
Goel et al., Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application, (2000),Cancer Research, 60:6964-6971.
Jiang et al., Enhanced effector functions of dimeric forms of IDEC—C2B8 (Rituximab), 1999,Blood, 94(10):86A (Abstract).
Slavin-Chiorini et al., A CDR-grafted (humanized) domain-deleted antitumor antibody, (1997),Cancer Biotherapy and Radiopharmaceuticals, 5(12):305-316.
Slavin-Chiorini et al., Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins, (1995),Cancer Research, 55:5957-5967.
Coloma et al., Design and production of novel tetravalent bispecific antibodies, (1997),Nature Biotechnology, 15(2):159-163.
Ghetie et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells, (1997),PNAS of USA, 94:7509-7514.
International Search Report dated Apr. 11, 2003, for PCT Application PCT/US02/02373.
Mieike et al., (Jun. 22, 2000) Stabllized, long-term expression of heterodimeric proteins from tricistronic mRNA,GENE, An International Journal on Genes, Genomes and Evoluation, Elsevier (Darmstadt, DE), p. 108.
Kolb et al., (1997) Expression of a recombinant Monoclonal Antibody from a Bicistronic mRNA,HYBRIDOMA, Mary Ann Libert, Inc., vol. 16 (No. 5), pp. 421-426.
Lo et al., (1998) Expression and secretion of an assembled tetrameric CH2-deleted antibody inE. coli, Human Antibodies and Hybridomas, ELSEVIER Science B.V. (Amsterdam) vol. 3 (No. 3), pp. 123-128—ABSTRACT.
Fussenegger et al (1997), Autoregulated Multicistronic Expression Vectors provide One-step Cloning of Regulated Product Gene Expression in Mammalian Cells,Biotechnol. Prog., American Chemical Society and American Institute of Chemical Engineers, pp. 733-740.
European Search Report, (Supplemental) Mar. 16, 2006, EP 02 80 2572.
Braslawsky Gary R
Chinn Paul
Hanna Nabil
Hariharan Kandasamy
Biogen Idec Inc.
Blanchard David J.
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
TAG-72 specific C H 2 domain deleted antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TAG-72 specific C H 2 domain deleted antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TAG-72 specific C H 2 domain deleted antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3934989